News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

AREVA Med LLC Med Presents Pharmacokinetics Data From Phase 1 Clinical Trial at SNMMI


5/17/2013 9:07:48 AM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

BETHESDA, Md., May 17, 2013 (GLOBE NEWSWIRE) -- AREVA Med, an AREVA subsidiary specializing in the development of new innovative therapies to fight cancer, announced today that it will present pharmacokinetics data on the company's ongoing Phase 1 clinical trial of its alpha radioimmunotherapy 212Pb-TCMC-Trastuzumab in patients with intra-abdominal cancers. The data will be presented at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting in Vancouver, June 8-12, 2013.

Help employers find you! Check out all the jobs and post your resume.

Read at GlobeNewswire


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES